Physician profile
Jeffrey E Aoki
NPI 1760463624
$8,557.91
in general payments reported to CMS, 2019-2025
24 companies · $1,144 in 2025
The $1,144 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,291 · 2020: $242 · 2021: $294 · 2022: $1,852 · 2023: $2,188 · 2024: $1,547 · 2025: $1,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,878.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,871.20 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,386.76 | 2023-2025 | Vraylar, Qulipta, Ubrelvy |
| Amgen INC. | $1,369.05 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $953.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $645.58 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $555.48 | 2022-2024 | Xifaxan, Trulance |
| Esperion Therapeutics, INC. | $544.64 | 2021-2023 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.88 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $217.51 | 2022-2024 | |
| Glaxosmithkline, LLC. | $176.96 | 2019-2023 | Arexvy, Shingrix |
| Kowa Pharmaceuticals America, INC. | $151.76 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $101.89 | 2022-2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $58.03 | 2025 | Voquezna |
| Dynavax Technologies Corporation | $57.68 | 2022-2024 | Heplisav-B |
| Teva Pharmaceuticals USA, INC. | $35.64 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $34.11 | 2019-2020 | |
| Sanofi Pasteur INC. | $32.14 | 2025 | |
| Astellas Pharma US INC | $31.83 | 2019 | |
| Abbott Laboratories | $30.67 | 2023 | Proclaim, Freestyle Libre 2 |
| Arbor Pharmaceuticals, INC. | $19.66 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.70 | 2025 | Trintellix |
| Dexcom, INC. | $13.62 | 2025 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $12.71 | 2019 | |
| Merck Sharp & Dohme LLC | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Aoki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.